Login to Your Account

Sage soars on phase III PPD data; expects filings next year for brexanolone

By Jennifer Boggs
Managing Editor

Thursday, November 9, 2017

Sage Therapeutics Inc. scored a big win Thursday, disclosing positive top-line data from its pivotal program testing brexanolone in postpartum depression, results that should support regulatory filings next year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription